Richard Stowell: Debarment Order, 13068-13069 [2013-04389]
Download as PDF
13068
Federal Register / Vol. 78, No. 38 / Tuesday, February 26, 2013 / Notices
were provided to subjects to participate
in the study; (10) a description of how
the sponsor(s) monitored the study and
ensured that the study was carried out
consistently with the study protocol;
and (11) a description of how
investigators were trained to comply
with GCP and to conduct the study in
accordance with the study protocol, and
a statement on whether written
commitments by investigators to comply
with GCP and the protocol were
obtained.
Section 312.120(c) specifies how
sponsors or applicants can request a
waiver for any of the requirements
under § 312.120(a)(1) and (b). Under
§ 312.120(c)(1), a waiver request must
contain at least one of the following: (1)
An explanation why the sponsor’s or
applicant’s compliance with the
requirement is unnecessary or cannot be
achieved, (2) a description of an
alternative submission or course of
action that satisfies the purpose of the
requirement, or (3) other information
justifying a waiver. A waiver request
may be submitted in an IND or in an
information amendment to an IND, or in
an application or in an amendment or
supplement to an application submitted
under 21 CFR part 314 or 601. Section
312.10 sets forth requirements for
sponsors who request waivers from FDA
for compliance with any of the
provisions in part 312, and § 314.90 sets
forth requirements for applicants who
request waivers from FDA for
compliance with §§ 314.50 through
314.81.
FDA has approval for the submission
of these waiver requests under OMB
control numbers 0910–0014 for part 312
and 0910–0001 for part 314. In addition
to the reporting requirements set forth
in table 1 of this document, there is also
a recordkeeping provision in
§ 312.120(d) stating how long sponsors
and applicants must retain records
required by § 312.120. In addition,
§ 312.120(b) states that any signed
written commitments by investigators
must be maintained by the sponsor or
applicant and made available for
Agency review upon request, and also
specifies sponsor recordkeeping of IECrelated information. Under § 312.120(d),
if a study is submitted in support of an
application for marketing approval,
records must be retained for 2 years
after an Agency decision on that
application; if a study is submitted in
support of an IND but not an application
for marketing approval, records must be
retained for 2 years after the submission
of the IND. The retention requirements
in § 312.57(c) for records and reports
required under part 312 apply to these
provisions, and are approved under
OMB control number 0910–0014.
We estimate that 237 companies will
submit a total of approximately 1,185
non-IND foreign clinical studies in
support of an IND or application for
marketing approval for a drug or
biological product. Hour burden
estimates vary due to differences in size,
complexity, and duration across studies,
and we estimate that complying with
§ 312.120 would take sponsors between
18 and 32 hours annually for each nonIND foreign clinical trial, totaling 37,920
hours (32 × 1,185).
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR Section
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
312.120 ................................................................................
237
5
1,185
32
37,920
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: February 21, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[Docket No. FDA–2012–N–0714]
335a(l)(1)(B)), of three felony counts
under Federal law for conduct relating
to the importation into the United States
of an article of food. Mr. Stowell was
given notice of the proposed debarment
and an opportunity to request a hearing
within the timeframe prescribed by
regulation. As of December 14, 2012,
Mr. Stowell had not responded. Mr.
Stowell’s failure to respond constitutes
a waiver of his right to a hearing
concerning this action.
Richard Stowell: Debarment Order
DATES:
[FR Doc. 2013–04422 Filed 2–25–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
AGENCY:
Food and Drug Administration,
tkelley on DSK3SPTVN1PROD with NOTICES
Submit applications for
termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
ADDRESSES:
HHS.
ACTION:
This order is effective February
26, 2013.
Notice.
SUMMARY: The U.S. Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
Richard Stowell for a period of 3 years
from importing articles of food or
offering such articles for importation
into the United States. FDA bases this
order on a finding that Mr. Stowell was
convicted, as defined in section
306(l)(1)(B) of the FD&C Act (21 U.S.C.
VerDate Mar<15>2010
16:35 Feb 25, 2013
Jkt 229001
FOR FURTHER INFORMATION CONTACT:
Kenny Shade, Office of Regulatory
Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD
20857, 301–796–4640.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
I. Background
Section 306(b)(1)(C) of the FD&C Act
(21 U.S.C. 335a(b)(1)(C)) permits FDA to
debar an individual from importing an
article of food or offering such an article
for import into the United States if FDA
finds, as required by section
306(b)(3)(A) of the FD&C Act (21 U.S.C.
335a(b)(3)(A)), that the individual has
been convicted of a felony for conduct
relating to the importation into the
United States of any food.
On July 27, 2011, Mr. Stowell was
convicted, as defined in section
306(l)(1)(B) of the FD&C Act, when the
U.S. District Court for the Southern
District of Florida accepted his plea of
guilty and entered judgment against him
for the following offenses: One count of
conspiracy to falsely label and misbrand
seafood, in violation of 18 U.S.C. 371;
one count of false labeling of seafood
under the Lacey Act, in violation of 16
U.S.C. 3372(d)(2) and 3373(d)(3)(A)(ii);
and one count of misbranding food, in
violation of 21 U.S.C. 331(a), 343(a)(1),
and 333(a)(2).
FDA’s finding that debarment is
appropriate is based on the felony
E:\FR\FM\26FEN1.SGM
26FEN1
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 38 / Tuesday, February 26, 2013 / Notices
convictions referenced herein for
conduct relating to the importation into
the United States of any food. The
factual basis for these convictions is as
follows: Mr. Stowell was the president
and sole shareholder of United Seafood
Imports, Inc. (United), a Florida based
seafood wholesaler engaged in various
aspects of purchasing, importing,
processing, packing, selling, and
exporting seafood products, including
shrimp.
Beginning in or around January 25,
2007, and continuing through on or
about August 7, 2009, Mr. Stowell did
knowingly and with the intent to further
the object of a conspiracy combine,
conspire, confederate, and agree with
others to commit an offense against the
United States. Specifically, Mr.
Stowell’s company United purchased
approximately one million pounds of
shrimp in boxes labeled ‘‘Shrimp,
Product of Thailand,’’ ‘‘Shrimp, Product
of Malaysia,’’ and ‘‘Shrimp, Product of
Indonesia.’’ Mr. Stowell then sent the
shrimp to another company, Shifco, and
instructed them to repackage and relabel
the shrimp as ‘‘Shrimp, Product of
Panama,’’ ‘‘Shrimp, Product of
Ecuador,’’ and ‘‘Shrimp, Product of
Honduras.’’ United, and employees
under Mr. Stowell’s direction and
control, managed and directed the
labeling operations of Shifco by
providing instructions and other
directives to them. Mr. Stowell’s
company then sold the shrimp that was
relabeled to a company who in turn
subsequently sold the shrimp to a
supermarket chain. This was in
violation of 18 U.S.C. 371.
On or about January 26, 2007, Mr.
Stowell purchased 180 cases of shrimp
valued at approximately $24,912 and
knowingly created and caused to be
created individual labels, preprinted
bags, and other documents falsely
identifying the shrimp as being
‘‘Shrimp, Product of Ecuador,’’ when in
truth and in fact he knew the shrimp
was a product of Malaysia. This was in
violation of 16 U.S.C. 3372(d)(2) and
3373(d)(3)(A)(ii).
On or about July 2, 2009, Mr. Stowell
knowingly engaged in an offense that
involved the introduction and delivery
for introduction into interstate
commerce of a food that was
misbranded, that is, approximately 52
cases of shrimp, with the intent to
defraud or mislead, in that Mr. Stowell
created and caused to be created
individual labels, preprinted bags, and
other documents falsely identifying the
shrimp as being a product of Panama
when in truth and in fact, he knew the
shrimp was a product of Indonesia. This
VerDate Mar<15>2010
16:35 Feb 25, 2013
Jkt 229001
was in violation of 21 U.S.C. 331(a),
333(a)(2), and 343(a)(1).
As a result of his conviction, on
September 24, 2012, FDA sent Mr.
Stowell a notice by certified mail
proposing to debar him for a period of
3 years from importing articles of food
or offering such articles for import into
the United States. The proposal was
based on a finding under section
306(b)(1)(C) of the FD&C Act that Mr.
Stowell was convicted of three felony
counts under Federal law for conduct
relating to the importation into the
United States of an article of food
because he: Conspired to falsely label
and misbrand seafood, falsely labeled
seafood under the Lacey Act, and
misbranded food.
The proposal was also based on a
determination, after consideration of the
factors set forth in section 306(c)(3) of
the FD&C Act (21 U.S.C. 335a(c)(3)) that
Mr. Stowell should be subject to a 3year period of debarment. The proposal
also offered Mr. Stowell an opportunity
to request a hearing, providing him 30
days from the date of receipt of the letter
in which to file the request, and advised
him that failure to request a hearing
constituted a waiver of the opportunity
for a hearing and of any contentions
concerning this action. Mr. Stowell
failed to request a hearing within the
timeframe prescribed by regulation and
has, therefore, waived his opportunity
for a hearing and waived any
contentions concerning his debarment
(21 CFR part 12).
II. Findings and Order
Therefore, the Associate
Commissioner for Regulatory Affairs,
Office of Regulatory Affairs, under
section 306(b)(1)(C) of the FD&C Act,
and under authority delegated to the
Associate Commissioner (Staff Manual
Guide 1410.21), finds that Mr. Richard
Stowell has been convicted of three
felony counts under Federal law for
conduct relating to the importation of an
article of food into the United States and
that he is subject to a 3-year period of
debarment.
As a result of the foregoing finding,
Mr. Stowell is debarred for a period of
3 years from importing articles of food
or offering such articles for import into
the United States, effective (see DATES).
Pursuant to section 301(cc) of the FD&C
Act (21 U.S.C. 331(cc)), the importing or
offering for import into the United
States of an article of food by, with the
assistance of, or at the direction of Mr.
Stowell is a prohibited act.
Any application by Mr. Stowell for
termination of debarment under section
306(d)(1) of the FD&C Act should be
identified with Docket No. FDA–2012–
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
13069
N–0714 and sent to the Division of
Dockets Management (see ADDRESSES).
All such submissions are to be filed in
four copies. The public availability of
information in these submissions is
governed by 21 CFR 10.20(j).
Publicly available submissions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: February 8, 2013.
Melinda K. Plaisier,
Acting Associate Commissioner for
Regulatory Affairs, Office of Regulatory
Affairs.
[FR Doc. 2013–04389 Filed 2–25–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2003–D–0128] (formerly
2003D–0236)
Draft Guidance for Industry:
Recommendations for Screening,
Testing, and, Management of Blood
Donors and Blood and Blood
Components Based on Screening
Tests for Syphilis; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft document entitled
‘‘Guidance for Industry:
Recommendations for Screening,
Testing, and Management of Blood
Donors and Blood and Blood
Components Based on Screening Tests
for Syphilis,’’ dated March 2013. The
draft guidance document provides
revised recommendations for screening
and testing of donors and management
of donations based on screening tests for
syphilis. The draft guidance is intended
for blood establishments that collect
Whole Blood or blood components,
including Source Plasma. The guidance
announced in this notice replaces the
draft guidance entitled, ‘‘Guidance for
Industry: Revised Recommendations for
Donor and Product Management Based
on Screening Tests for Syphilis,’’ dated
June 2003. In addition, the draft
guidance, when finalized, is intended to
supersede the FDA memorandum to
registered blood establishments dated
December 12, 1991, entitled,
‘‘Clarification of FDA Recommendations
for Donor Deferral and Product
Distribution Based on the Results of
Syphilis Testing.’’
E:\FR\FM\26FEN1.SGM
26FEN1
Agencies
[Federal Register Volume 78, Number 38 (Tuesday, February 26, 2013)]
[Notices]
[Pages 13068-13069]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-04389]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0714]
Richard Stowell: Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Food and Drug Administration (FDA) is issuing an
order under the Federal Food, Drug, and Cosmetic Act (FD&C Act)
debarring Richard Stowell for a period of 3 years from importing
articles of food or offering such articles for importation into the
United States. FDA bases this order on a finding that Mr. Stowell was
convicted, as defined in section 306(l)(1)(B) of the FD&C Act (21
U.S.C. 335a(l)(1)(B)), of three felony counts under Federal law for
conduct relating to the importation into the United States of an
article of food. Mr. Stowell was given notice of the proposed debarment
and an opportunity to request a hearing within the timeframe prescribed
by regulation. As of December 14, 2012, Mr. Stowell had not responded.
Mr. Stowell's failure to respond constitutes a waiver of his right to a
hearing concerning this action.
DATES: This order is effective February 26, 2013.
ADDRESSES: Submit applications for termination of debarment to the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Kenny Shade, Office of Regulatory
Affairs, Food and Drug Administration, 12420 Parklawn Dr., Rockville,
MD 20857, 301-796-4640.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act (21 U.S.C. 335a(b)(1)(C))
permits FDA to debar an individual from importing an article of food or
offering such an article for import into the United States if FDA
finds, as required by section 306(b)(3)(A) of the FD&C Act (21 U.S.C.
335a(b)(3)(A)), that the individual has been convicted of a felony for
conduct relating to the importation into the United States of any food.
On July 27, 2011, Mr. Stowell was convicted, as defined in section
306(l)(1)(B) of the FD&C Act, when the U.S. District Court for the
Southern District of Florida accepted his plea of guilty and entered
judgment against him for the following offenses: One count of
conspiracy to falsely label and misbrand seafood, in violation of 18
U.S.C. 371; one count of false labeling of seafood under the Lacey Act,
in violation of 16 U.S.C. 3372(d)(2) and 3373(d)(3)(A)(ii); and one
count of misbranding food, in violation of 21 U.S.C. 331(a), 343(a)(1),
and 333(a)(2).
FDA's finding that debarment is appropriate is based on the felony
[[Page 13069]]
convictions referenced herein for conduct relating to the importation
into the United States of any food. The factual basis for these
convictions is as follows: Mr. Stowell was the president and sole
shareholder of United Seafood Imports, Inc. (United), a Florida based
seafood wholesaler engaged in various aspects of purchasing, importing,
processing, packing, selling, and exporting seafood products, including
shrimp.
Beginning in or around January 25, 2007, and continuing through on
or about August 7, 2009, Mr. Stowell did knowingly and with the intent
to further the object of a conspiracy combine, conspire, confederate,
and agree with others to commit an offense against the United States.
Specifically, Mr. Stowell's company United purchased approximately one
million pounds of shrimp in boxes labeled ``Shrimp, Product of
Thailand,'' ``Shrimp, Product of Malaysia,'' and ``Shrimp, Product of
Indonesia.'' Mr. Stowell then sent the shrimp to another company,
Shifco, and instructed them to repackage and relabel the shrimp as
``Shrimp, Product of Panama,'' ``Shrimp, Product of Ecuador,'' and
``Shrimp, Product of Honduras.'' United, and employees under Mr.
Stowell's direction and control, managed and directed the labeling
operations of Shifco by providing instructions and other directives to
them. Mr. Stowell's company then sold the shrimp that was relabeled to
a company who in turn subsequently sold the shrimp to a supermarket
chain. This was in violation of 18 U.S.C. 371.
On or about January 26, 2007, Mr. Stowell purchased 180 cases of
shrimp valued at approximately $24,912 and knowingly created and caused
to be created individual labels, preprinted bags, and other documents
falsely identifying the shrimp as being ``Shrimp, Product of Ecuador,''
when in truth and in fact he knew the shrimp was a product of Malaysia.
This was in violation of 16 U.S.C. 3372(d)(2) and 3373(d)(3)(A)(ii).
On or about July 2, 2009, Mr. Stowell knowingly engaged in an
offense that involved the introduction and delivery for introduction
into interstate commerce of a food that was misbranded, that is,
approximately 52 cases of shrimp, with the intent to defraud or
mislead, in that Mr. Stowell created and caused to be created
individual labels, preprinted bags, and other documents falsely
identifying the shrimp as being a product of Panama when in truth and
in fact, he knew the shrimp was a product of Indonesia. This was in
violation of 21 U.S.C. 331(a), 333(a)(2), and 343(a)(1).
As a result of his conviction, on September 24, 2012, FDA sent Mr.
Stowell a notice by certified mail proposing to debar him for a period
of 3 years from importing articles of food or offering such articles
for import into the United States. The proposal was based on a finding
under section 306(b)(1)(C) of the FD&C Act that Mr. Stowell was
convicted of three felony counts under Federal law for conduct relating
to the importation into the United States of an article of food because
he: Conspired to falsely label and misbrand seafood, falsely labeled
seafood under the Lacey Act, and misbranded food.
The proposal was also based on a determination, after consideration
of the factors set forth in section 306(c)(3) of the FD&C Act (21
U.S.C. 335a(c)(3)) that Mr. Stowell should be subject to a 3-year
period of debarment. The proposal also offered Mr. Stowell an
opportunity to request a hearing, providing him 30 days from the date
of receipt of the letter in which to file the request, and advised him
that failure to request a hearing constituted a waiver of the
opportunity for a hearing and of any contentions concerning this
action. Mr. Stowell failed to request a hearing within the timeframe
prescribed by regulation and has, therefore, waived his opportunity for
a hearing and waived any contentions concerning his debarment (21 CFR
part 12).
II. Findings and Order
Therefore, the Associate Commissioner for Regulatory Affairs,
Office of Regulatory Affairs, under section 306(b)(1)(C) of the FD&C
Act, and under authority delegated to the Associate Commissioner (Staff
Manual Guide 1410.21), finds that Mr. Richard Stowell has been
convicted of three felony counts under Federal law for conduct relating
to the importation of an article of food into the United States and
that he is subject to a 3-year period of debarment.
As a result of the foregoing finding, Mr. Stowell is debarred for a
period of 3 years from importing articles of food or offering such
articles for import into the United States, effective (see DATES).
Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the
importing or offering for import into the United States of an article
of food by, with the assistance of, or at the direction of Mr. Stowell
is a prohibited act.
Any application by Mr. Stowell for termination of debarment under
section 306(d)(1) of the FD&C Act should be identified with Docket No.
FDA-2012-N-0714 and sent to the Division of Dockets Management (see
ADDRESSES). All such submissions are to be filed in four copies. The
public availability of information in these submissions is governed by
21 CFR 10.20(j).
Publicly available submissions may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: February 8, 2013.
Melinda K. Plaisier,
Acting Associate Commissioner for Regulatory Affairs, Office of
Regulatory Affairs.
[FR Doc. 2013-04389 Filed 2-25-13; 8:45 am]
BILLING CODE 4160-01-P